Triple-negative breast cancer (TNBC) is more prone to metastasis and recurrence than other breast cancer subtypes. This study aimed to identify genes that can act as diagnostic biomarkers for predicting lymph node metastasis in TNBC patients. The transcriptomic data of TNBC with or without lymph node metastasis was acquired from TCGA, and the differentially expressed genes were identified. Further, logistic-regression method has been used to identify the top 15 genes (or 15 gene signatures) based on their ability to predict metastasis (AUC>0.65). These 15 gene signatures were used to develop machine learning techniques based prediction models; Gaussian Naive Bayes classifier outperformed other with AUC>0.80 on both training and validation datasets. The best model failed drastically on nine independent microarray datasets obtained from GEO. We investigated the reason for the failure of our best model, and it was observed that the certain genes in 15 gene signatures were showing opposite regulating trends, i.e., genes are upregulated in TCGA-TNBC patients while it is downregulated on other microarray datasets or vice-versa. In conclusion, the 15 gene signatures may act as diagnostic markers for the detection of lymph node metastatic status in TCGA dataset, but quite challenging across multiple platforms. We also identified the prognostic potential of the 15 selected genes and found that overexpression of ZNRF2, FRZB, and TCEAL4 was associated with poor survival with HR>2.3 and p-value≤0.05. In order to provide services to the scientific community, we developed a webserver named 'MTNBCPred' for the prediction of metastatic and non-metastatic lymph node status of TNBC patients (http://webs.iiitd.edu.in/raghava/mtnbcpred/ ).
Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting
